Skip to main content

Clinical Trials Using Degarelix

Review the clinical trials studying degarelix on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-21 of 21

Two Studies for Patients with Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a Higher Gene Risk Score, The Guidance Trial
Status: Active
Location: 553 locations
Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Status: Active
Location: 324 locations
Treating Prostate Cancer That Has Come Back after Surgery with Apalutamide and Targeted Radiation Based on PET Imaging, INDICATE Trial
Status: Active
Location: 305 locations
Comparing Different Endocrine Therapies for Male Breast Cancer, ETHAN Trial
Status: Active
Location: 8 locations
Standard of Care Treatment (Hormonal Therapy and Stereotactic Ablative Radiation Therapy) Alone or in Combination with Niraparib, Abiraterone and Prednisone for the Treatment of Metastatic Prostate Cancer, KNIGHTS Trial
Status: Active
Location: 7 locations
2141-V11 in Combination with Standard Therapy for the Treatment of Prostate Cancer Prior to Surgery
Status: Active
Location: 7 locations
Talazoparib with Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer, TRIPLE-PRO Trial
Status: Active
Location: 5 locations
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for the Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
Status: Active
Location: 3 locations
Degarelix with or without pTVG-AR and with or without Nivolumab for the Treatment of Prostate Cancer
Status: Active
Location: 2 locations
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Status: Active
Location: 2 locations
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Status: Active
Location: 2 locations
A Study of Personalized Apalutamide Treatment for Improving Quality of Life in Patients with Prostate Cancer after Post Operative Radiation, PROSTATE-IQ Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Enzalutamide and Talazoparib with Androgen Deprivation Therapy for the Treatment of Patients with Prostate Cancer that is Metastatic to the Lymph Nodes at Diagnosis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Testosterone and ZEN-3694 followed by Enzalutamide and ZEN-3694 for the Treatment of Asymptomatic Patients with Metastatic Castration-Resistant Prostate Cancer, The COSMYC Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
MR-Linac-Guided Stereotactic Body Radiation Therapy with Androgen Deprivation Therapy for the Treatment of Locally Recurrent Prostate Adenocarcinoma
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Adaptive Androgen Deprivation Therapy and Docetaxel for the Treatment of Metastatic Castration Sensitive Prostate Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Metastasis-Directed Radiotherapy for the Treatment of Men with Oligometastatic Prostate Cancer, METANOVA Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Androgen Deprivation Therapy and SBRT versus SBRT Alone for the Treatment of Unfavorable Intermediate Risk Prostate Cancer
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Evaluation of 177Lu rhPSMA-10.1 and Degarelix before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer, Nautilus Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Copanlisib in Combination with Degarelix in Treating High-Risk Localized Prostate Cancer prior to Radical Prostatectomy, The CHARIOT Trial
Status: Temporarily Closed to Accrual
Location: 7 locations